Table 4 Association between HPV and LC3B status on overall and disease-free survival in oropharyngeal SCC (n = 47)
LC3B and HPV status | Overall survival | Disease-free survival | ||
|---|---|---|---|---|
| Â | HR* (95% CI) | P value | HR* (95% CI) | P value |
A. Joint-effects presentation | ||||
 HPV positive/Low LC3B (n = 18) | 1.00 |  | 1.00 |  |
 HPV positive/High LC3B (n = 11) | 2.85 (0.77–10.47) | 0.115 | 1.91 (0.36–10.22) | 0.449 |
 HPV negative/Low LC3B (n = 8) | 0.82 (0.24–2.82) | 0.756 | 1.45 (0.30–7.15) | 0.647 |
 HPV negative/High LC3B (n = 10) | 4.76 (1.23–18.48) | 0.024* | 2.83 (0.57–0.57) | 0.205 |
B. Stratified presentation | ||||
 HPV positive/Low LC3B (n = 18) | 1.00 |  | 1.00 |  |
 HPV positive/High LC3B (n = 11) | 2.95 (0.66–13.25) | 0.159 | 1.83 (0.28–11.79) | 0.524 |
 HPV negative/Low LC3B (n = 8) | 1.00 |  | 1.00 |  |
 HPV negative/High LC3B (n = 10) | 18.71 (1.3–270.24) | 0.032* | 3.35 (0.31–36.78) | 0.323 |